ReviewPediatric nephrology (Berlin, Germany)2018
Biomarkers to detect rejection after kidney transplantation.
Review in Pediatric nephrology (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05335538 (The Role of TruGraf® to Optimize Outcomes in Pediatric Renal Transplantation), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of TruGraf® to Optimize Outcomes in Pediatric Renal Transplantation
Who cites it
9 citing papers in PubMed.
- Clinical implications of plasma sADAM10: integrating renal function, histopathology and prognostic outcomes in chronic kidney disease and kidney transplantation.Frontiers in immunology · 2026Article
- A Lesson of Immunosuppression in Renal Transplant: Retreat or Hold?The Yale journal of biology and medicine · 2023Observational
- Molecular Markers of Kidney Transplantation Outcome: Current Omics Tools and Future Developments.International journal of molecular sciences · 2022Review
- New Insights from Metabolomics in Pediatric Renal Diseases.Children (Basel, Switzerland) · 2022Review
- Biomarkers of alloimmune events in pediatric kidney transplantation.Frontiers in pediatrics · 2022Review
- Emerging monitoring technologies in kidney transplantation.Pediatric nephrology (Berlin, Germany) · 2021Review
- Challenges of Diagnosing Antibody-Mediated Rejection: The Role of Invasive and Non-Invasive Biomarkers.Medicina (Kaunas, Lithuania) · 2021Review
- Therapies for Chronic Allograft Rejection.Frontiers in pharmacology · 2021Review
- Single-cell Transcriptomics and Solid Organ Transplantation.Transplantation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detecting acute rejection in kidney transplantation has been traditionally done using histological analysis of invasive allograft biopsies, but this method carries a risk and is not perfect. Transplant professionals have been working to develop more accurate or less invasive biomarkers that can predict acute rejection or subsequent worse allograft survival. These biomarkers can use tissue, blood or urine as a source. They can comprise individual molecules or panels, singly or in combination, across different components or pathways of the immune system. This review highlights the most recent evidence for biomarker efficacy, especially from multicenter trials.
Indexed as
Identifiers
28631040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.